Search company, investor...

Founded Year



Other Investors | Alive

About Inflazyme Pharmaceuticals

Juli4D is an online lottery platform specializing in providing access to major Asian lottery markets, particularly in the online gambling industry. The company offers services that allow users to bet on lottery numbers, track lottery results, and manage their gambling accounts. Juli4D is recognized for its partnerships with Toto SGP and Toto HK, offering a trusted platform for lottery enthusiasts. It was founded in 1992 and is based in Richmond, British Columbia.

Headquarters Location

5600 Parkwood Way Ste 425

Richmond, British Columbia, V6V 2M2,




Latest Inflazyme Pharmaceuticals News

Inflazyme, Hoechst Marion Roussel to Develop Asthma/Allergy Drugs

Jan 6, 2018

Inflazyme Pharmaceuticals Ltd. (Richmond, BC, Canada) and Hoechst Marion Roussel (Kansas City, MO) have signed a collaborative agreement to develop two novel series of compounds—Inflazyme's IPL576 series and Hoechst Marion Roussel's H1/NK1 dual antagonists—for the treatment of asthma and allergies. Under terms of the agreement, Inflazyme will receive an up-front fee and an equity investment by Hoechst Marion Roussel totaling up to US$16 million. In addition, Inflazyme will be entitled to payments totaling US$75 million if development milestones specified in the agreement are achieved. The agreement gives Inflazyme immediate access to cash for the development of IPL576 and H1/NK1, while minimizing dilution to the company's common shareholders. Inflazyme expects to enter Phase I clinical trials with IPL576,092 in the UK before the end of June. IPL576,092 is Inflazyme's lead clinical candidate from its IPL576 class of compounds, which is based on a molecule originally isolated from a sea sponge by researchers at the University of British Columbia and the University of Alberta. Pre-clinical studies have demonstrated that IPL576,092 may have the efficacy of inhaled glucocorticoids without the related side effects. Hoechst Marion Roussel's H1/NK1 dual antagonists combine in a single molecule an antihistamine and a neuro-peptide inhibitor. In pre-clinical studies to date, H1/NK1 dual antagonist compounds have demonstrated antagonist activity at both the H1 and NK1 receptors, which indicates that they may have the potential to relieve both the itchiness and the congestion associated with allergies. In addition to the development agreement, Inflazyme and Hoechst Marion Roussel have agreed to collaborate on research into the mode of action and cellular targets for IPL576. The two companies will share ownership of joint discoveries from the research collaboration. Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat serious inflammatory diseases such as asthma, rheumatoid arthritis, allergies, psoriasis and inflammatory bowel disease. Hoechst Marion Roussel is the pharmaceutical company of Hoechst AG (Frankfurt, Germany). For more information: Ian McBeath, President and CEO, Inflazyme Pharmaceuticals Ltd., Suite 425, 5600 Parkwood Way, Richmond, British Columbia V6V 2M2, Canada. Tel: 604-279-8511. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .

Inflazyme Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Inflazyme Pharmaceuticals founded?

    Inflazyme Pharmaceuticals was founded in 1992.

  • Where is Inflazyme Pharmaceuticals's headquarters?

    Inflazyme Pharmaceuticals's headquarters is located at 5600 Parkwood Way, Richmond.

  • What is Inflazyme Pharmaceuticals's latest funding round?

    Inflazyme Pharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Inflazyme Pharmaceuticals?

    Investors of Inflazyme Pharmaceuticals include Domain Associates.

  • Who are Inflazyme Pharmaceuticals's competitors?

    Competitors of Inflazyme Pharmaceuticals include Sagimet Biosciences, Array Biopharma, BioMarck Pharmaceuticals, Idenix Pharmaceuticals, Quincy Bioscience and 7 more.


Compare Inflazyme Pharmaceuticals to Competitors

Targeted Cell Therapies

Targeted Cell Therapies is an early-stage biopharmaceutical company focused on the development of biotherapeutics for a variety of human diseases. The company specializes in a technology platform that enables the conversion of injectable biologics into oral medications, simplifying the delivery process and potentially improving patient quality of life. It is based in Worcester, Massachusetts.

Topigen Pharmaceuticals

Topigen Pharmaceuticals is a company focused on respiratory research within the pharmaceutical industry. The company's main offerings include the development and distribution of various biological research products such as antibodies, assay kits, biology cells, and DNA testing kits. These products are primarily used in the research and development sector of the pharmaceutical industry. It was founded in 2000 and is based in Montreal, Quebec.

Quincy Bioscience Logo
Quincy Bioscience

Quincy Bioscience is a biotechnology company that operates in the health and wellness industry, with a focus on supporting cognitive function and addressing health challenges associated with aging. The company's main offerings include the development and commercialization of novel technologies, specifically the patented ingredient apoaequorin, which is used in products designed to support memory and overall cognitive health. Quincy Bioscience primarily serves the dietary supplement market. It was founded in 2004 and is based in Madison, Wisconsin.


Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.


REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.

arGentis Pharmaceuticals

arGentis Pharmaceuticals is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.